Zhao Ke, Hu Hong-Tao, Li Hai-Liang, Cheng Hong-Tao, Zhao Ya-Nan, Hang Yuan, Yao Quan-Jun
Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.
PLoS One. 2025 May 28;20(5):e0323829. doi: 10.1371/journal.pone.0323829. eCollection 2025.
To explore the safety and effectiveness of partial splenic embolization (PSE) in patients with hypersplenism and hepatocellular carcinoma (HCC) and to compare the efficacy of superselective and non-superselective embolization of splenic artery branches.
We retrospectively analyzed 64 patients with HCC who underwent PSE between August 2020 and December 2022. The patients were categorized into two groups based on different treatment plans: Group A (n=33) underwent superselective embolization and Group B (n=31) underwent non-superselective embolization of the splenic artery branches. The safety and effectiveness of the two methods were evaluated along with changes in peripheral blood cells [mainly white blood cells (WBC) and red blood cells (RBC)] and platelet (PLT) counts at different time points after PSE. Postoperative adverse events were also compared between the two groups.
The technical success rate was 100% for both procedures. The PLT and WBC counts of the two groups significantly increased one week after PSE (P<0.05), and there was no statistically significant difference in the RBC count changes. At follow-up (4, 16, and 24 weeks), the PLT and WBC counts remained consistent at levels which were significantly different from those before PSE (P<0.05). However, the RBC counts were not significantly different (P>0.05). An independent sample t-test was used to compare the differences in blood counts between the two groups at the same time point. There were no statistically significant differences in PLT, WBC, and RBC counts between Group A and Group B at any time point after PSE (P>0.05). The incidence of fever and pain in Group B was significantly higher than that in Group A (P<0.05).
Partial splenic artery embolization is a safe and effective treatment option for hypersplenism. Both splenic artery branch superselective and non-superselective embolization strategies demonstrated comparable outcomes. However, superselective embolization exhibited a lower incidence of postprocedural complications than non-superselective embolization.
探讨部分脾栓塞术(PSE)治疗脾功能亢进合并肝细胞癌(HCC)患者的安全性和有效性,并比较脾动脉分支超选择性与非超选择性栓塞的疗效。
回顾性分析2020年8月至2022年12月期间接受PSE的64例HCC患者。根据不同治疗方案将患者分为两组:A组(n = 33)行脾动脉分支超选择性栓塞,B组(n = 31)行脾动脉分支非超选择性栓塞。评估两种方法的安全性和有效性,以及PSE后不同时间点外周血细胞[主要是白细胞(WBC)和红细胞(RBC)]和血小板(PLT)计数的变化。同时比较两组术后不良事件。
两种手术的技术成功率均为100%。两组患者PSE后1周PLT和WBC计数显著升高(P < 0.05),RBC计数变化无统计学差异。随访(4、16和24周)时,PLT和WBC计数维持在与PSE前显著不同的水平(P < 0.05)。然而,RBC计数无显著差异(P > 0.05)。采用独立样本t检验比较两组在同一时间点的血细胞计数差异。PSE后任何时间点A组和B组的PLT、WBC和RBC计数均无统计学差异(P > 0.05)。B组发热和疼痛的发生率显著高于A组(P < 0.05)。
部分脾动脉栓塞术是治疗脾功能亢进的一种安全有效的选择。脾动脉分支超选择性和非超选择性栓塞策略均显示出相似的结果。然而,超选择性栓塞术后并发症的发生率低于非超选择性栓塞。